Antiplasmodial, beta-haematin inhibition, antitrypanosomal and cytotoxic activity in vitro of novel 4-aminoquinoline 2-imidazolines. 2008

Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.

A novel series of 4-aminoquinoline-containing 2-imidazolines were synthesized via a one-pot 3-component condensation reaction of amine, aldehyde and isocyanoacetate. The products were obtained in high yield as well as purity and were evaluated directly against two strains of Plasmodium falciparum and Trypanosoma brucei. Compound was the most active across all parasites with ED(50) = 3.3 nM against a chloroquine (CQ)-sensitive 3D7 strain, ED(50) = 33 nM against a CQ-resistant K1 strain and ED(50) = 70 nM against T. brucei. Several compounds were able to inhibit formation of beta-haematin in vitro, suggesting haemozoin formation in the malaria parasite as a possible target. On the other hand, evaluation against a human KB cell line revealed that the compounds were generally non-cytotoxic to the host cells.

UI MeSH Term Description Entries
D007624 KB Cells This line KB is now known to be a subline of the ubiquitous KERATIN-forming tumor cell line HeLa. It was originally thought to be derived from an epidermal carcinoma of the mouth, but was subsequently found, based on isoenzyme analysis, HeLa marker chromosomes, and DNA fingerprinting, to have been established via contamination by HELA CELLS. The cells are positive for keratin by immunoperoxidase staining. KB cells have been reported to contain human papillomavirus18 (HPV-18) sequences. HeLa-KB Cells,Cell, HeLa-KB,Cell, KB,Cells, HeLa-KB,Cells, KB,HeLa KB Cells,HeLa-KB Cell,KB Cell
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011804 Quinolines
D006420 Hemeproteins Proteins that contain an iron-porphyrin, or heme, prosthetic group resembling that of hemoglobin. (From Lehninger, Principles of Biochemistry, 1982, p480) Hemeprotein,Heme Protein,Heme Proteins,Protein, Heme,Proteins, Heme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D014346 Trypanosoma brucei brucei A hemoflagellate subspecies of parasitic protozoa that causes nagana in domestic and game animals in Africa. It apparently does not infect humans. It is transmitted by bites of tsetse flies (Glossina). Trypanosoma brucei,Trypanosoma brucei bruceus,Trypanosoma bruceus,brucei brucei, Trypanosoma,brucei, Trypanosoma brucei,bruceus, Trypanosoma,bruceus, Trypanosoma brucei
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D048288 Imidazolines Compounds based on reduced IMIDAZOLES containing a single double bond. Imidazoline

Related Publications

Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
January 2004, Experimental parasitology,
Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
November 2010, European journal of medicinal chemistry,
Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
January 2015, European journal of medicinal chemistry,
Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
November 2013, European journal of medicinal chemistry,
Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
October 2016, European journal of medicinal chemistry,
Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
June 2007, Biochemical pharmacology,
Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
October 2018, Bioorganic chemistry,
Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
September 2012, Bioorganic & medicinal chemistry letters,
Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
August 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Chitalu C Musonda, and Vanessa Yardley, and Renata C Carvalho de Souza, and Kanyile Ncokazi, and Timothy J Egan, and Kelly Chibale
July 2014, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!